FINWIRES · TerminalLIVE
FINWIRES

Campbell's Unlikely to See Immediate Relief From Demand Pressures, RBC Capital Markets Says

By

Campbell's (CPB) appears to be moving in the wrong direction and is unlikely to see immediate relief from continuing demand pressures, RBC Capital Markets said in a note Wednesday.

The brokerage said it is about in line with consensus estimates for the company's fiscal Q3 results, which are expected on June 8.

Analysts said the company continues to struggle to improve volume and share performance.

The company's Snacks segment is facing greater competitive pressure and consumer pullback, while its meals and beverages division is seeing signs of likely deterioration, according to the note.

From a demand perspective, packaged food is still facing "consumer pressure, pricing-driven volume elasticity payback, and elevated competitive promotional activity," the brokerage said.

RBC Capital Markets has a sector perform rating on Campbell's and a $23 price target.

Price: $21.41, Change: $+0.42, Percent Change: +1.98%

Related Articles

Wire

C3.ai's Fiscal Q4 Results 'Good Step in Right Direction,' Wedbush Says

C3.ai's (AI) fiscal Q4 results are a "good step in the right direction," with restructuring savings expected in H2 of fiscal 2027, Wedbush said in a Thursday research note.Wedbush said that with Tom Siebel back in the role of chief executive officer and the company's restructuring effort largely in the rearview mirror, it believes that C3.ai is now positioned to begin focusing on execution on its growth story.With C3.ai expecting fiscal 2027 revenue in the range of $210 million to $240 million and adjusted operating loss between $128 million and $160 million, compared with Wall Street estimates of $224.7 million and $144.2 million loss, Wedbush said that the revenue midpoint implies a step down from fiscal 2026 but the reduced loss guide underscores cost discipline.Wedbush reiterated the company's outperform rating with $15 price target.Price: $10.64, Change: $-0.07, Percent Change: -0.65%

$AI
Wire

UnitedHealth, CVS, Cigna Seen Benefiting From Utilization Trends, AI Upside, Morgan Stanley Says

UnitedHealth (UNH), CVS Health (CVS) and Cigna (CI) are among the managed-care companies that could benefit from improving utilization trends and potential artificial intelligence-driven efficiency gains across the healthcare system, Morgan Stanley said in a note Thursday.The firm said early signs of softer utilization have supported recent gains in managed-care stocks. The group has delivered a series of medical-loss-ratio beats in Q1 and some companies raising guidance. However, it noted that investors are still awaiting clearer confirmation of underlying trends and utilization signals remaining mixed ahead of Q2 results.AI adoption is increasingly embedded across managed-care operations, including prior authorization, call centers, provider portals, care management, pharmacy utilization and payment integrity.Morgan Stanley said UnitedHealth stands out as a leading "AI enabler," particularly through Optum Insight initiatives, which support both efficiency gains and potential revenue upside.The firm's scenario analysis assumes 0.5% to 2.0% AI-driven insurance margin expansion, which could translate into an illustrative 18% to 71% EPS upside across managed-care companies. It added that administrative workflows, particularly prior authorization, remain key areas of automation potential.Morgan Stanley boosted its price targets on UnitedHealth, CVS Health, Elevance Health (ELV), Centene (CNC), Molina Healthcare (MOH), and Humana (HUM).Price: $399.90, Change: $+22.90, Percent Change: +6.07%

$CI$CNC$CVS$ELV$HUM$MOH$UNH
Wire

Nexalin Technology Wins US Patent Protecting Neurostimulation Method Through 2042

Nexalin Technology (NXL) said the US Patent and Trademark Office issued a patent expected to provide core intellectual property protection for its dynamic frequency stimulation method through 2042, strengthening its competitive position in deep-brain neurostimulation for depression and insomnia.The patent covers methods including transcranial alternating current stimulation, the company said Thursday in a statement.Price: $0.50, Change: $-0.03, Percent Change: -5.41%

$NXL